Psychiatry Investig.
2017 May;14(3):360-367. 10.4306/pi.2017.14.3.360.
An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia
- Affiliations
-
- 1Department of Psychiatry, Mental Health Center of Inner Mongolia, Inner Mongolia, Hohhot, China. dongshenglv@163.com
- 2Department of Psychiatry, the First Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, Hohhot, China.
- 3Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
- 4Department of Psychiatry, Second Xiangya Hospital of Central South University, Changsha, China.
- KMID: 2378652
- DOI: http://doi.org/10.4306/pi.2017.14.3.360
Abstract
OBJECTIVE
The aim of this study was to investigate ziprasidone plasma concentration, daily dose and clinical efficacy and safety in Han Chinese and Mongolian patients with first-episode schizophrenia.
METHODS
A total of 123 inpatients affected by schizophrenia were recruited from the Mental Health Center of Inner Mongolia in China. Ziprasidone plasma concentration, clinical efficacy and side effects were systematically evaluated at baseline, and at 1, 2, 4, and 6 weeks. Metabolic measures such as changes in weight, body mass index (BMI), fasting blood glucose (FBG), triglycerides, and cholesterol, were also recorded.
RESULTS
90 patients completed the study. Compared with Han patients, on average, Mongolian patients received a significantly higher ziprasidone dosage for adequate symptom control during the 6-week period and had a lower plasma concentration-to-dose ratio. The Mongolian patients also experienced greater increases in weight and BMI. No significant differences between the two ethnic groups were found in the rate of reduction in the Positive and Negative Syndrome Scale (PANSS) score, Treatment Emergent Symptom Scale (TESS) total score, FBG, triglycerides, cholesterol or Q-Tc interval.
CONCLUSION
Compared to Han Chinese patients, Mongolian patients appeared to have increased ziprasidone clearance and require higher doses to achieve effective treatment for schizophrenia.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Safety and Efficacy of Ziprasidone: Post-Marketing Surveillance Study in Korea
- Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia
- Naturalistic, Retrospective Study on Clinical Experience of Ziprasidone in 3 University Hospitals
- Body Weight Gain and Metabolic Changes in Patients with Schizophrenia during 12-Week Randomized Treatment of Ziprasidone and Risperidone
- Relationship between Risperidone-Induced Therapeutic Response and Plasma Homovanillic Acid and 5-Hydroxyindoleacetic Acid Levels in Patients with Schizophrenia
